6 Jan 2021 10:27
6 January 2021
Β
Β
Oncimmune Holdings plc
Β
("Oncimmune" or the "Company")
Β
Total Voting Rights
Β
Β
In accordance with the Disclosure Guidance and Transparency Rules (DTR 5.6), Oncimmune makes the following disclosure with respect to the share capital and voting rights of the Company.
Β
As at 31 December 2020, the Company's issued share capital was 63,662,446 ordinary shares of Β£0.01 each with voting rights. The Company does not hold any shares in treasury.
Β
The above figure of 63,662,446 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Β
Β
Β
For further information:
Β
Oncimmune Holdings plc
Ron Kirschner, Company Secretary
contact@oncimmune.co.uk
Β
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
Β
N+1 Singer (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
Β
WG Partners (Joint Broker)
David Wilson, Chris Lee
+44 (0)203 705 9321
Β
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
Follow the stocks